Compare Nasdaq Inc (NDAQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Zimmer Biomet Holdings Inc — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Nasdaq Inc is far larger — about 3× Zimmer Biomet Holdings Inc's market cap, and Nasdaq Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| NDAQ | ZBH | |
|---|---|---|
Market Cap | $51.96B | $17.36B |
Sector | Financials | Health |
52-Week High | $100.98 | $107.71 |
52-Week Low | $76.85 | $79.58 |
Enterprise Value | $59.02B | $24.40B |
Dividend Yield | 1.22% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $90.24, down 1.53% today, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding expectations, and maintains robust profitability with a net income margin of 23.03%. Recent news highlights strategic growth, including the acquisition of Nasdaq Fund Secondaries by NPM, expanding its platform beyond direct company shares.
The outlook for NDAQ is positive, supported by organic revenue growth and strategic acquisitions, though risks include market volatility and execution challenges. With 61.11% of analysts rating it a buy and a price target implying ~19% upside, the stock presents a growth opportunity for investors focused on financial infrastructure expansion, balanced by monitoring debt levels and competitive pressures.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
